Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6215054 | 0.99 | PDE10A (0.39) | PDE10AKDM4EGPR3XIAPCYP2A6 | |
| SCHEMBL2103250 | 0.81 | TSHR (0.41) | KDM4ECYP2A6CYP1A2TDP1CYP2C9 | |
| SCHEMBL6216145 | 0.75 | CYP11B1 (0.48) | PDE10ACYP1A2ADRA2AADRA2BADRA2C | |
| SCHEMBL14533532 | 0.74 | KDM4E (0.44) | PDE10AKDM4EGPR3XIAPCYP2A6 | |
| Hydrochloric Acid SCHEMBL6213427 | 0.73 | CYP11B1 (0.47) | PDE10ACYP1A2ADRA2AADRA2BADRA2C | |
| SCHEMBL15414353 | 0.73 | KDM4E (0.46) | PDE10AKDM4EGPR3XIAPCYP2A6 | |
| SCHEMBL2103783 | 0.73 | TAAR1 (0.46) | CYP1A2ADRA1DADRA1AADRA1BCYP2C9 | |
| SCHEMBL6214324 | 0.70 | PLAU (0.43) | KDM4ECYP2A6NPC1ADRA2AADRA2B | |
| SCHEMBL4629510 | 0.69 | TAAR1 (0.40) | KDM4ENPC1HSD17B10 | |
| Hydrochloric Acid SCHEMBL6216864 | 0.69 | PLAU (0.42) | KDM4ECYP2A6NPC1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975602-B1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| EP-0975602-A4 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0975602-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998046572-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | PDE10A 415/4885KDM4E 3834/4885GPR3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.